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Background 
Stem cell biology is one of the most important topics 
of the century in biology and medicine. Understanding 
the mechanisms by which stem cells self-regenerate in 
an undifferentiated state will improve our 
understanding of human development and diseases. 
Stem cells are known to have important characteristics 
such as self-renewal, in which they undergo unlimited 
asymmetric division [1, 2]. Somatic stem cells are able 
to maintain and regenerate normal tissues by means of 
asymmetric and self-renewing divisions; therefore, 
defects in their proliferation capacity may result in cell 
aging or tumorigenesis. In contrast to somatic stem 
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Abstract  
Esophageal carcinoma is one of the most malignant of all tumors, and affected patients have low survival rates. The lack of good 
prognostic and therapeutic targets indicate the mysterious biology of this cancer. Recently, studies with cancer stem cells (CSCs) 
revealed some clues for better understanding of cancer biology and development. CSCs are derived from normal stem cells and 
have essential roles in tumor initiation and development of malignancies, such as esophageal carcinoma. Self-renewal studies in 
CSCs have improved our understanding of the factors that regulate CSCs behaviour and may result in improved prognostic 
markers and new therapeutic targets. Abnormal activity of major cell signaling pathways such as Shh, Notch, and Wnt play 
important roles in converting stem cells from normal to cancerous. This manuscript reviews the importance of several processes in 
the maintenance of esophageal CSCs and introduces probable useful markers for CSC based ESCC therapy.  
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cells, other cells within tissues are transient, have 
limited proliferation, and eventually differentiate.  
It has been shown that most cancers originate from a 
subpopulation of proliferating cells in tissues known as 
cancer stem cells (CSCs). CSCs were first observed in 
acute myelogenous leukemia [3-5], and subsequently 
have been observed in breast, colon, and prostate 
cancers [6-9]. The presence of CSCs in different tumor 
types indicates the tumorigenic role of a small 
subpopulation of cancer stem cells that support the 
maintenance of tumor cell growth [5, 10].  
Three cancer propagation models have been 
proposed. The CSCs model describes two different 
kinds of cells; a small population of tumor cells with 
tumorigenic ability (tumorigenic cells), and their 
derived cells (non-tumorigenic cells), which have 
relatively less proliferative ability than tumorigenic 
cells and no potential for tumor formation. The 
stochastic model refers to a high proportion of 
tumorigenic cells in a tumor with genome instability, 
resulting in mutations and the generation of different 
genetically malignant clones in a tumor [11]. Finally, 
the interconversion model refers to tumorigenic cells 
switching between hyper-and hypo-proliferation 
statuses, which represent tumorigenic and 
non-tumorigenic cells, respectively [12].   
It is believed that the derivation of non-tumorigenic 
cells from tumorigenic cells in some tumors is similar 
to the generation of differentiated cells from stem cells 
by asymmetric division in normal tissues. These 
tumorigenic cells are a result of initiating and required 
carcinogenic mutations in most malignancies, such as 
gastrointestinal tumors, because mature cells have not 
had sufficient time to accumulate such mutations [5]. 
Strict genetic programs regulate the relatively stable 
population of stem cells in normal tissues and organs 
[13, 14], whereas lack of such homeostatic regulation 
in cancer cells results in an elevated number of 
self-renewing cells, which cause an increase in tumor 
size. Elucidation of these regeneration mechanisms is 
critical to our understanding of cancer cell biology 
[15]. 
Esophageal carcinoma is one of the most malignant 
of all tumors.  It is the sixth leading cause of 
cancer-related deaths in the world, and the 5-year 
survival rate in affected patients is approximately 42% 
[16]. Incidence of esophageal carcinoma has increased 
significantly in western countries in the past 30 years, 
and 95% of the histological subtype is esophageal 
squamous cell carcinoma (ESCC) or adenocarcinoma 
[17-20]. Northeast Iran is one of the high-risk areas in 
the world; this area is located in the “Central Asian 
Esophageal Cancer Belt,” which is along the Silk Road 
and extends from north Iran eastward to China [21, 
22]. 
Understanding the molecular mechanisms involved 
in esophageal tumorigenesis is necessary for the 
improvement of prognosis and treatment. Of the many 
genetic alterations involved in the tumorigenesis of 
esophageal cancer [23], only a small part are associated 
with the clinicopathological features of tumor cells; 
hence, identification of genes associated with the 
clinicopathological features is necessary.  
It has been shown that signaling pathways such as 
Shh, Notch, and Wnt, regulating the self-renewal of 
stem cells, play important roles in tumorigenesis [24, 
25]. Here we review correlations between these 
pathways and self-renewal properties of esophageal 
cell carcinoma. 
Wnt signaling and its role in regulation of 
CSCs 
The Wnt/ß-catenin signaling pathway responsible for 
the regulation of self-renewal in normal stem cells and 
also plays an important role in tumorigenesis [26, 27].  
The Wnt proteins prime the Wnt signaling pathway, 
bind to Frizzled receptors (Fz), and activate an 
inhibitor called Dishevelled (Dsh). Dsh acts as an 
inhibitor for a destruction complex (APC, Axin, and 
Gsk3) responsible for the ubiquitination and 
degradation of ß-catenin. Undegraded ß-catenin enters 
the nucleus and activates transcription factors involved 
in oncogenesis, such as T-cell factor (TCF), whereas in 
the absence of Wnt signals, the destruction complex 
ubiquitinates ß-catenin for degradation by proteasomes 
(Figure 1) [28, 29]. Wnt signaling has been reported to 
be involved in the maintenance of intestinal epithelial 
[30] and skin stem cells [31]. 
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Figure 1 Actions and interactions of major cell signaling pathways in Esophageal CSCs 
There are several important signaling pathways which have complex interactions together in Esophageal CSCs maintenance and miRNAs 
have a noticeable role in regulation of such pathways (see the text for details). 
 
Axin, a suppressor in the Wnt signaling pathway, 
induces the ubiquitination and degradation of β-catenin 
and inhibits ß-catenin from entering the nucleus.  
Axin underexpression has been observed in ESCC [32]. 
The Axin-ectopic expression targets ß-catenin for 
ubiquitination and degradation, and inhibits 
proliferation of stem cells both in vivo and in vitro [33]. 
Although the main role of Axin is regulation of the 
Wnt/ß-catenin pathway, it is also involved in other 
signaling pathways, such as that of TGF-ß, an inducer 
for smad3 activation and translocation to the nucleus, 
where smad3 acts as a transcription factor for several 
target genes that include p21, p15, p16, and RUNX3 
[34]. Dickkopf-1 (DKK1), another Wnt signaling 
inhibitor, binds to the low-density lipoprotein 
receptor-related protein-5/6 (LRP5/6) and blocks the 
interaction between Fz and Wnt-1. This results in 
ß-catenin degradation and slowing of proliferation [35]. 
A relationship between DKK1 overexpression and 
esophageal tumorigenesis has been previously reported 
[36]. Recently we have analyzed the Msi1 expression 
in ESCC patients and showed its significant 
overexpression in 41.5% of tumors (unpublished data). 
Msi1 is one of the DKK3 inhibitors and can induce 
Wnt pathway via the DKK1 degradation. This result 
may also confirm the involvement of Wnt signaling in 
the ESCC tumorigenesis. Mutations in some subunits 
of destruction complexes such as APC can inactivate 
the complex in colon cancer and other malignancies 
[37]. Furthermore, overexpression of some components 
of this pathway, such as Wnt gene products, has been 
observed in epithelial cancers [38]. Wnt signaling, one 
of the most common signaling pathways in CSCs, 
targets several gene products.  LGR5, one of the Wnt 
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signaling targets, is a G protein-coupled receptor that 
has been shown to be expressed in cryptal precursor 
cells and involved in esophageal [39], colorectal [40], 
hepatocellular [41], and endometrial cancers [42]. 
Abnormal nuclear E-cadherin expression is associated 
with esophageal carcinogenesis by regulation of 
ß-catenin availability, resulting in altered expression of 
Wnt target genes [43, 44]. It is believed that E-cadherin 
overexpression and binding to ß-catenin competitively 
inhibits ß-catenin binding to Axin and the APC 
destruction complex proteins, resulting in an increase 
in cytoplasmic ß-catenin levels, which then enter the 
nucleus and activate Wnt target genes [44]. 
Additionally, ß-catenin is involved in cell–cell 
adhesion via an E-cadherin-mediated cell adhesion 
system, in which it binds to the cytoplasmic domain of 
cadherins to link the cadherin to the actin cytoskeleton; 
therefore, a decrease in ß-catenin levels leads to tissue 
disorganization [45]. Underexpression of ß-catenin in 
ESCC patients is associated with tumour 
undifferentiation and poor prognosis, and is also 
involved in the early stages of esophageal 
tumorigenesis [46].  
CD44, a type Ι transmembrane glycoprotein , is one 
of the major CSC surface markers.  It monitors the 
extracellular environment and plays essential roles in 
cell proliferation, migration and intercellular 
interactions [47-49].  Moreover, it facilitates the 
tumor cell distribution via the vessels during metastasis 
through its ligand-analogy for p-selectin receptor on 
endothelial cells [50]. CD44 is a Wnt target gene in 
ESCC [51]. 
Recently, we have revealed a significant correlation 
not only between PYGO2 and EGFR mRNA 
expression in ESCC, but also between PYGO2/EGFR 
expression and clinicopathological features. There is a 
mutual positive correlation between PYGO2 and 
EGFR in ESCC progression  . EGFR may stabilizes the 
cytoplasmic ß-catenin and consequently increases its 
accumulation in the nucleus where it can prime gene 
expression of Wnt target genes in presence of other 
factors such as BCL9 and PYGO2 (Figure 1)  [52]. 
Therefore, Wnt signaling pathway plays important 
roles in the CSCs of ESCC. 
Notch signaling and its role in regulation of 
CSCs 
Notch signaling is involved in cell proliferation and 
apoptosis. The Notch gene family encodes the 
membrane receptors Notch1 and Notch4, which are 
activated by ligands such as Delta and Jagged. Notch 
activation occurs through cleavage via a specific 
metalloprotease and γ-secretase, in which an 
intracellular domain is released. The intracellular 
domain of Notch (ICN) translocates to the nucleus 
where it binds to the CSL complex (CBF1, suppressor 
of Hairless/ Lag1) and activates several Notch 
signaling target genes, including cyclin D1, Hes1, and 
Nuclear Factor-κB (NF-κB) (Figure 1). In the absence 
of ICN, the CSL complex in the nucleus inhibits Notch 
target gene expression [53]. Deregulation in Notch 
signaling results in unlimited cell proliferation and 
tumorigenesis in colon, lung, head and neck, cervical, 
renal, and pancreatic cancers [53, 54]. In addition, it 
has been reported that deregulation of Notch signaling 
leads to a tumor suppressor effect seen in skin and 
hepatocellular cancers [53]. The exact role of Notch 
signaling depends on the cell context, in which it may 
have either oncogenic or tumor suppressor roles in 
tumorigenesis.  Notch1 and ICN overexpression in 
SHG-44 glioma cells have significant roles in colony 
formation and the development of neurosphere-like 
colonies [55]. Notch1 overexpression in 
erythroleukemia cells influences the cell cycle and 
apoptosis by regulation of Bcl-xL, p21cip1, p27kip1, 
NF-κB and Rb [56].  
Deregulation of TGF-ß and Notch signaling may 
result in Barrett’s-related adenocarcinoma. Moreover, 
expression of Hes-1 and Sox-9, two important Notch 
signaling targets, is upregulated in Barrett’s-associated 
adenocarcinoma tissues and cell lines [57]. 
Epithelial-mesenchymal transition (EMT), an 
important process during embryogenesis and tumor 
metastasis, begins with a decrease in cell adherence 
[58].  Twist1 and Mastermind-like 1 (MAML1) 
transcription factors, which are involved in Wnt and 
Notch signaling, respectively, are the main factors in 
the EMT process [59, 60]. Twist1 transcription factor is 
an inhibitor of E-cadherin expression and one of the 
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most important proteins in cell adherence [61]. 
We previously showed the probable correlation 
between Wnt and Notch signaling pathways in ESCC 
tumorigenesis by means of MAML1 and TWIST1 
causing aggressive behavior in ESCC tumor cells 
through the EMT process. We demonstrated a 
significant correlation between MAML-1 and Twist1 
overexpression and lymph node metastasis and surgical 
staging of tumors. Twist1 overexpression was 
associated with tumor depth. Moreover, Twist1 and 
MAML1 mRNA expression was significantly higher in 
advanced tumor stages (stages 3 and 4) than in less 
advanced stages in ESCC patients [62].  
The hairy and enhancer of split gene families 
(HES/HEY), basic helix-loop-helix (bHLH) 
transcription factors, are the major downstream target 
genes of Notch signaling pathway. They are included in 
both self renewal and tumorigenesis [63]. Expressional 
analyses showed that the members of these families are 
either misregulated or significantly correlated with 
indices of poor prognosis in ESCC (data not shown). 
All together, these data prove the involvement of Notch 
signaling pathway in ESCC progression.     
Hedgehog signaling and its role in regulation 
of CSCs 
The Hedgehog (Hh) signaling pathway has multiple 
roles in embryogenesis, tumorigenesis, tissue 
regeneration, and homeostasis [64, 65]. It begins with 
the binding of secreted Hh factors to Ptch1 receptors, 
resulting in Ptch1 deactivation. Ptch1 is an inhibitor of 
Smo. Subsequently, Smo activation triggers a 
cytoplasmic cascade that translocates the Gli1 zinc 
finger transcription factor into the nucleus as an 
activator of hedgehog target genes BMP4, FOXA2, 
ISL1 and FOXM1 (Figure 1) [66-68]. The Hh pathway 
is associated with carcinogenesis in skin, prostate, and 
breast [69]. Esophageal cancer is one of the most 
malignant of all tumors and affected patients have low 
survival rates. The best treatment is tumor resection 
and chemoradiotherapy (CRT); however, only 25% of 
patients respond to CRT, whereas in 75% of patients 
we see no response due to the emergence of 
tumorigenic cells, which self-renew and are 
CRT-resistant [70, 71]. CRT-resistant patients with 
relapsed tumors express Gli-1, one of the Hh signaling 
components [72]; therefore, Gli1 is a suitable marker 
for diagnosis of CRT-resistant patients. Moreover, Gli1 
is expressed in half of ESCC tumors [73]. In general, 
Hh signaling activation in normal tissues is under strict 
control and every aberrant activation results in 
tumorigenesis via cancer stem cells, in which only a 
small fraction of tumor cells can repopulate.  
Hippo signaling and its role in regulation of 
CSCs 
The Hippo signaling pathway has an important role in 
the balance between cell proliferation and apoptosis in 
response to cell density changes [74]. Additionally, this 
pathway is involved in stem cell expansion and tissue 
regeneration [75, 76]. Mst1/2 kinases are the main 
components of Hippo signaling, and are activated by 
apoptotic stress. Mst1/2 and other mediators, such as 
Lats1/2 and Mob1, inhibit the YAP/TAZ transcription 
co-activators from entering the nucleus by binding to 
the cytoplasmic anchor 14-3-3 protein (Figure 1) [77]. 
Mouse studies revealed that YAP is involved in the 
Wnt signaling pathway through the interaction with 
β-catenin, leading to overexpression of the Wnt target 
genes Sox2 and Snai2 [78]. Moreover, YAP is involved 
in the regulation of several transcription factors, such 
as RUNX2, SMAD7, ERBB4, and P73 [79-82]. YAP 
overexpression is involved in the tumorigenesis of 
multiple human malignancies that include colon, 
ovarian, and prostate cancers [83] by inducing EMT, 
apoptosis inhibition, and other processes [84].  
Overexpression of YAP is associated with poor 
prognosis and low survival rates in ESCC patients [85].  
Cancer testis antigens in CSCs 
Another group of proteins linked to cancer stem cells 
are the cancer testis antigens (CTAs) [86]. Although 
CTAs are expressed in a limited spectrum of normal 
tissues such as testis, placenta, and the other immature 
cells, they are expressed widely in several tumors 
[87-89]. SSX is one of the most important CTAs that 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 6 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
binds to domains associated with Bmi1 [90]. SSX is 
involved in embryogenesis by means of its role in EMT, 
an essential process during embryogenesis [86].  
MAGE-A4 is another member of the CTA family 
involved in regulation of gene expression by 
association with the PIAS2 transcription factor. The 
C-terminal domain (CTD) of MAGE-A4 inhibits Miz1, 
a transcription factor involved in p21 expression; 
therefore, MAGE-A4 indirectly inhibits cell cycle 
arrest by p21 [91]. The CTD of MAGE-A4 also 
induces apoptosis through p53 [92]. MAGE-A4 
overexpression has been reported in ESCC and bladder 
cancer [93, 94]. We observed overexpression of the 
CTAs MAGE-A4, LAGE1, and NY-ES O1 in 90.2, 
39.0, and 41.4% of ESCC patients respectively, and 
97.5% of our samples overexpressed at least one CTA. 
Moreover, we observed a direct correlation between 
MAGE-A4 overexpression and lymph node metastasis 
and tumor stage (p < 0.05), which implicates 
MAGE-A4 as a good prognostic marker for ESCC 
[94].  
Chromatin structure in CSCs 
Although signaling pathways and CTAs have important 
roles in the regulation of stem cell function, it is 
believed that epigenetic modifications in chromatin, 
such as histone modifications, DNA methylation, and 
nucleosomal remodelling also influence self-renewal in 
stem cells [95], and epigenetic aberrations are involved 
in carcinogenesis and tumor progression [96]. 
Many pluripotent genes, such as OCT4, SOX2, and 
NANOG, which are transcriptionally silenced by the 
polycomb group (PcG) proteins, are located in 
chromatin areas with trimethylated H3K27 histones 
[97].  Addition of the demethylator 5-azacytidine 
resulted in overexpression of these self-renewal 
markers [98]; however, methylation can result in 
diverse outcomes; for example, trimethylation of lys9 
and 27 of histone 3 (H3K9, H3K27) resulted in 
chromatin inactivation, whereas H3K4 trimethylation 
or acetylation is associated with transcription [99].  
To conserve stem cells, genes involved in stem cell 
differentiation must be down-regulated.  PcGs, such 
as polycomb repressive complexes PRC1 and PRC2 
are responsible for this important task.  EZH2 and 
BMI1 are PRC2 and PRC1 members, respectively 
[100]. EZH2 is a histone methyltransferase that is 
responsible for the trimethylation of histone H3 at 
lysine 27 (H3K27me3) via its SET domain and acts as 
a suppressor of expression of tumor suppressor genes, 
including DAB2IP [101], E-cadherin [102], and 
RUNX3 [103]. EZH2 is involved in tumorigenesis of 
several cancers, and EZH2 gene silencing reduces 
tumor cell invasiveness [104]. Abnormal expression of 
EZH2 and BMI1 was observed in 14% and 16.9% of 
ESCC tumors, respectively, and EZH2 expression was 
associated with clinicopathological features such as 
size, metastasis, and survival rates in ESCC patients 
[105]. A significant association between 
clinicopathological features and BMI1 overexpression 
in ESCC patients has been observed, indicating that the 
BMI1 plays an important role in ESCC. BMI1 
overexpression was higher in stage Ι/ΙΙ tumors 
compared to stage ΙΙΙ/ΙV tumors; whereas, BMI1 
expression was significantly lower in patients without, 
than in those with, metastatic lymph nodes [106].  
MicroRNAs as the CSC markers in ESCC 
MicroRNAs (miRNAs), members of non-coding RNAs, 
are important molecules in regulation of a variety of 
biological processes such as cell proliferation and 
apoptosis, and their abnormal functions will results in 
tumorigenesis [107,108]. miRNAs are responsible for 
negative post-transcriptional gene regulation. They 
bind to the  3' untranslated region  (3’-UTR) of 
target-mRNAs and lead mRNAs degradation or 
cease-translation [109].  
Functionally, mature miRNAs are produced via a 
sequential process from pri-miRNAs precursors. This 
process is mediated by two RNase III enzymatic 
complexes; Drosha/DGCR8 (Pasha) and Dicer (RLC 
complex) which are found in the nucleus and 
cytoplasm respectively. [110, 111]. In cytoplasm, 
mature miRNAs along with RNA-induced silencing 
complex (RISC) can bind to the 3'-UTR of target 
mRNAs and operate either cleavage of target mRNAs 
or miRNA-dependent translational inhibition [112].  
Deregulated miRNAs which are related to the 
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tumorigenesis are often known as oncogenic 
microRNAs (oncomiRs). The first mammalian 
oncomiR, miR17-92 polycistron, was observed in 
mouse B-cell lymphoma model [113].  It is 
transcriptionally activated by the c-Myc and plays 
oncogenic role in various malignancies through 
targeting several tumor suppressor genes such as PTEN 
and E2F1 [114, 115]. miR-21 is another well known 
oncomiRs that targets different tumor suppressors such 
as MASPIN [116]. miR-21 overexpression is reported 
in several malignancies such as esophageal, pancreatic 
and colon cancers [117-119]. Some miRNAs such as 
miR-34a and miR-128 have suppressing roles in 
tumorigenesis and function as tumor suppressor via 
targeting Notch-1/2 and BMI-1, respectively [120, 121]. 
Notch 1/2 and BMI1 are the major component of 
Notch signaling and chromatin remodeling, 
respectively.  In addition, underexpression of some 
miRNAs is involved in EMT process of tumor cells.  
Several studies have pointed that underexpressed 
miR-200 and miR-205 is significantly correlated with 
tumor metastasis [122, 123]. miRNAs expression has 
undeniable roles in ESCC. While underexpression of 
some miRNAs such as miR-518b, miR-143 and 
miR-145  is significantly correlated with lymph node 
metastasis and tumor invasion [124, 125] miR-21 has a 
remarkable higher level of expression in the sera of 
metastatic ESCC samples in comparison with the 
non-metastatic tumors [126, 127].  It has been shown 
that OCT4, SOX2 and KLF4 as the master regulators 
of CSCs are the targets of miR-145 [128, 129]. Since 
the most important characteristic of a biomarker is its 
accessibility, circulating biomarkers (such as miRNAs) 
in human serum  are the best means of malignancies’ 
diagnosis and can be used as a prognostic markers in a 
variety of cancers including ESCC [130-134]. It is 
worthy to note that such markers have a noticeable 
stability in severe conditions which is really idealistic 
in the case of sample preparation [127].  
To sum up, deregulation of miRNAs in various cancers 
highlighted their critical role in cancer development 
acting as either oncogene or tumor suppressor [135]. 
Having considered the Figure1, there are strict 
connections among different CSC signaling pathways 
in ESCC, which can be governed by specific master 
mediators in the cell such as miRNAs. 
Conclusion 
CSC pathways analysis is one the main helping ways 
to understand CSCs involvement in tumor growth and 
development. Considering the higher efficiency of 
therapeutic modalities in the primary levels of tumor 
development, it is valuable to compare malignant cells 
biology and CSCs behavior due to prominent roles of 
CSCs in initiation of tumorigenesis.  
Regarding to the CSCs features such as self-renewal 
and proliferative capacity and drug resistance, it seems 
that the tumor metastasis and relapse may be associated 
with CSCs. Although chemotherapeutic modalities 
discard most of the tumor cells, CSCs resist and stay 
dormant for a long time and they will be able to 
reactivate and repropagate. Besides working on mouse 
modeling which provides tumors resemble to the 
human tumors would prepare strong tools to assess the 
CSCs drug sensitivity.   
CSCs distribution and maintenance is depended to 
various factors in tumor microenvironment such as 
oxygen [136]. Hypoxic targeted therapy would be an 
efficient way to ruin the CSC niches. Regarding to the 
presence of similar markers in normal and CSCs, most 
of therapeutic strategies will results in normal stem cell 
damage, emphasizing the introducing more specific 
CSC markers. Indeed, finding the efficient markers 
from the mentioned pathways which have discussed in 
this review will prepare more specific markers in CSC 
based ESCC therapy. Moreover, as mentioned above 
the miRNA networks in CSCs also play an important 
role in EMT, which is orchestrated by the tumor 
microenvironment signals [137], presenting such 
factors as useful targets in CSC therapy. 
In this review we focused on the role of different 
self-renewal signaling pathways in esophageal cancer 
to introduce the probable more specific ESCC cancer 
stem cell markers. Signaling pathways such as Notch, 
Wnt, Sonic hedgehog (Shh), and others, form a 
complex net and communicate with each other, and 
these relationships play important roles in the 
preservation and function of cancer stem cells [138, 
139]. It also has been demonstrated that CSC gene 
expression profiles in some cancers are associated with 
diagnosis and CRT-resistance. These signaling 
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pathways have helped researchers to identify new 
specific targets for esophageal cancer therapy. However, 
one challenge is the presence of these signaling 
pathways in somatic stem cells; therefore, targeting 
these components will also affect normal stem cells, 
and indeed, finding new methods to isolate CSCs 
within tumors will offer improved CT in esophageal 
cancer patients. Unfortunately, the majority of cancer 
therapeutic strategies won’t be able to target only the 
CSCs and they target the other cancer cells which 
results in tumor relapses. Although, there are some 
specific anti CSC drugs for some cancers [140, 141], 
their clinical success depends on rational clinical 
consequences. Indeed, to reach such idealistic aims for 
CSC targeted therapy in solid tumors, further research 
should be performed to introduce the more efficient 
CSC markers. 
Acknowledgements 
References 
1. Donovan PJ, Gearhart J. The end of the 
beginning for pluripotent stem cells. Nature. 
2001, 414:92-97 
2. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin 
of metastasis and heterogeneity in solid 
tumours. Lancet Oncol. 2002, 3:508-513 
3. Blair A, Hogge DE, Ailles LE, Lansdorp PM, 
Sutherland HJ. Lack of expression of thy-1 
(cd90) on acute myeloid leukemia cells with 
long-term proliferative ability in vitro and in 
vivo. Blood. 1997, 89:3104-3112 
4.  Hope KJ, Jin L, Dick JE. Acute myeloid 
leukemia originates from a hierarchy of 
leukemic stem cell classes that differ in 
self-renewal capacity. Nat Immunol. 2004, 
5:738-743 
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. 
Stem cells, cancer, and cancer stem cells. 
Nature. 2001, 414:105-111 
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, 
Morrison SJ, Clarke MF. Prospective 
identification of tumorigenic breast cancer cells. 
Proc Natl Acad Sci U S A. 2003, 100:3983-3988 
7. Collins AT, Berry PA, Hyde C, Stower MJ, 
Maitland NJ. Prospective identification of 
tumorigenic prostate cancer stem cells. Cancer 
Res. 2005, 65:10946-10951 
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A 
human colon cancer cell capable of initiating 
tumour growth in immunodeficient mice. 
Nature. 2007, 445:106-110 
9. Singh SK, Clarke ID, Terasaki M, Bonn VE, 
Hawkins C, Squire J, Dirks PB. Identification 
of a cancer stem cell in human brain tumors. 
Cancer Res. 2003, 63:5821-5828 
10. Clarke MF, Fuller M. Stem cells and cancer: 
Two faces of eve. Cell. 2006, 124:1111-1115 
11. Nowell PC. The clonal evolution of tumor cell 
populations. Science. 1976, 194:23-28 
12. Gupta PB, Chaffer CL, Weinberg RA. Cancer 
stem cells: Mirage or reality? Nat Med. 2009, 
15:1010-1012 
13. Morrison SJ, Qian D, Jerabek L, Thiel BA, 
Park IK, Ford PS, Kiel MJ, Schork NJ, 
Weissman IL, Clarke MF. A genetic 
determinant that specifically regulates the 
frequency of hematopoietic stem cells. J 
Immunol. 2002, 168:635-642 
14. Muller-Sieburg CE, Cho RH, Sieburg HB, 
Kupriyanov S, Riblet R. Genetic control of 
hematopoietic stem cell frequency in mice is 
mostly cell autonomous. Blood. 2000, 
95:2446-2448 
15. Clarke MF. A self-renewal assay for cancer 
stem cells. Cancer Chemother Pharmacol. 2005, 
56 Suppl 1:64-68 
16. Rice TW, Rusch VW, Apperson-Hansen C, Allen 
MS, Chen LQ, Hunter JG, Kesler KA, Law S, 
Lerut TE, Reed CE, Salo JA, Scott WJ, 
Swisher SG, Watson TJ, Blackstone EH. 
Worldwide esophageal cancer collaboration. 
Dis Esophagus. 2009, 22:1-8 
17. Brown LM, Devesa SS, Chow WH. Incidence of 
adenocarcinoma of the esophagus among white 
americans by sex, stage, and age. J Natl 
Cancer Inst. 2008, 100:1184-1187 
18. Holmes RS, Vaughan TL. Epidemiology and 
pathogenesis of esophageal cancer. Semin 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 9 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
Radiat Oncol. 2007, 17:2-9 
19. Jemal A, Siegel R, Xu J, Ward E. Cancer 
statistics, 2010. CA Cancer J Clin. 60:277-300 
20. Daly JM, Fry WA, Little AG, Winchester DP, 
McKee RF, Stewart AK, Fremgen AM. 
Esophageal cancer: Results of an american 
college of surgeons patient care evaluation 
study. J Am Coll Surg. 2000, 190:562-572; 
discussion 572-563 
21. Kamangar F, Malekzadeh R, Dawsey SM, 
Saidi F. Esophageal cancer in northeastern 
iran: A review. Arch Iran Med. 2007, 10:70-82 
22. Taghavi N, Biramijamal F, Sotoudeh M, 
Khademi H, Malekzadeh R, Moaven O, Memar 
B, A'Rabi A, Abbaszadegan MR. P16ink4a 
hypermethylation and p53, p16 and mdm2 
protein expression in esophageal squamous cell 
carcinoma. BMC Cancer. 10:138 
23. Meltzer SJ. The molecular biology of 
esophageal carcinoma. Recent Results Cancer 
Res. 1996, 142:1-8 
24. Polakis P. Wnt signaling and cancer. Genes 
Dev. 2000, 14:1837-1851 
25. Wechsler-Reya R, Scott MP. The developmental 
biology of brain tumors. Annu Rev Neurosci. 
2001, 24:385-428 
26. Cadigan KM, Nusse R. Wnt signaling: A 
common theme in animal development. Genes 
Dev. 1997, 11:3286-3305 
27. Reya T, Duncan AW, Ailles L, Domen J, 
Scherer DC, Willert K, Hintz L, Nusse R, 
Weissman IL. A role for wnt signalling in 
self-renewal of haematopoietic stem cells. 
Nature. 2003, 423:409-414 
28. Barker N, Clevers H. Catenins, wnt signaling 
and cancer. Bioessays. 2000, 22:961-965 
29. Reya T, Clevers H. Wnt signalling in stem cells 
and cancer. Nature. 2005, 434:843-850 
30. Batlle E, Henderson JT, Beghtel H, van den 
Born MM, Sancho E, Huls G, Meeldijk J, 
Robertson J, van de Wetering M, Pawson T, 
Clevers H. Beta-catenin and tcf mediate cell 
positioning in the intestinal epithelium by 
controlling the expression of ephb/ephrinb. Cell. 
2002, 111:251-263 
31. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, 
Birchmeier W. Beta-catenin controls hair 
follicle morphogenesis and stem cell 
differentiation in the skin. Cell. 2001, 
105:533-545 
32. Nakajima M, Fukuchi M, Miyazaki T, Masuda 
N, Kato H, Kuwano H. Reduced expression of 
axin correlates with tumour progression of 
oesophageal squamous cell carcinoma. Br J 
Cancer. 2003, 88:1734-1739 
33. Tsukamoto AS, Grosschedl R, Guzman RC, 
Parslow T, Varmus HE. Expression of the int-1 
gene in transgenic mice is associated with 
mammary gland hyperplasia and 
adenocarcinomas in male and female mice. 
Cell. 1988, 55:619-625 
34. Furuhashi M, Yagi K, Yamamoto H, Furukawa 
Y, Shimada S, Nakamura Y, Kikuchi A, 
Miyazono K, Kato M. Axin facilitates smad3 
activation in the transforming growth factor 
beta signaling pathway. Mol Cell Biol. 2001, 
21:5132-5141 
35. Gregory CA, Singh H, Perry AS, Prockop DJ. 
The wnt signaling inhibitor dickkopf-1 is 
required for reentry into the cell cycle of 
human adult stem cells from bone marrow. J 
Biol Chem. 2003, 278:28067-28078 
36. Li S, Qin X, Liu B, Sun L, Zhang X, Li Z, Shan 
B, You J, Zhou Q. Dickkopf-1 is involved in 
invasive growth of esophageal cancer cells. J 
Mol Histol.  
37. Taipale J, Beachy PA. The hedgehog and wnt 
signalling pathways in cancer. Nature. 2001, 
411:349-354 
38. Bafico A, Liu G, Goldin L, Harris V, Aaronson 
SA. An autocrine mechanism for constitutive 
wnt pathway activation in human cancer cells. 
Cancer Cell. 2004, 6:497-506 
39. von Rahden BH, Kircher S, Lazariotou M, 
Reiber C, Stuermer L, Otto C, Germer CT, 
Grimm M. Lgr5 expression and cancer stem 
cell hypothesis: Clue to define the true origin of 
esophageal adenocarcinomas with and without 
barrett's esophagus? J Exp Clin Cancer Res. 
30:23 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 10 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
40. McClanahan T, Koseoglu S, Smith K, Grein J, 
Gustafson E, Black S, Kirschmeier P, Samatar 
AA. Identification of overexpression of orphan 
g protein-coupled receptor gpr49 in human 
colon and ovarian primary tumors. Cancer Biol 
Ther. 2006, 5:419-426 
41. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, 
Kenetaka K, Asaka M, Hirohashi S. 
Overexpression of orphan g-protein-coupled 
receptor, gpr49, in human hepatocellular 
carcinomas with beta-catenin mutations. 
Hepatology. 2003, 37:528-533 
42. Sun X, Jackson L, Dey SK, Daikoku T. In 
pursuit of leucine-rich repeat-containing g 
protein-coupled receptor-5 regulation and 
function in the uterus. Endocrinology. 2009, 
150:5065-5073 
43. Kuphal F, Behrens J. E-cadherin modulates 
wnt-dependent transcription in colorectal 
cancer cells but does not alter wnt-independent 
gene expression in fibroblasts. Exp Cell Res. 
2006, 312:457-467 
44. Salahshor S, Naidoo R, Serra S, Shih W, Tsao 
MS, Chetty R, Woodgett JR. Frequent 
accumulation of nuclear e-cadherin and 
alterations in the wnt signaling pathway in 
esophageal squamous cell carcinomas. Mod 
Pathol. 2008, 21:271-281 
45. Schuhmacher C, Becker I, Oswald S, Atkinson 
MJ, Nekarda H, Becker KF, Mueller J, Siewert 
JR, Hofler H. Loss of immunohistochemical 
e-cadherin expression in colon cancer is not 
due to structural gene alterations. Virchows 
Arch. 1999, 434:489-495 
46. de Castro J, Gamallo C, Palacios J, 
Moreno-Bueno G, Rodriguez N, Feliu J, 
Gonzalez-Baron M. Beta-catenin expression 
pattern in primary oesophageal squamous cell 
carcinoma. Relationship with clinicopathologic 
features and clinical outcome. Virchows Arch. 
2000, 437:599-604 
47. Du L, Wang H, He L, Zhang J, Ni B, Wang X, 
Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. 
Cd44 is of functional importance for colorectal 
cancer stem cells. Clin Cancer Res. 2008, 
14:6751-6760 
48. Kristiansen G, Winzer KJ, Mayordomo E, 
Bellach J, Schluns K, Denkert C, Dahl E, 
Pilarsky C, Altevogt P, Guski H, Dietel M. 
Cd24 expression is a new prognostic marker in 
breast cancer. Clin Cancer Res. 2003, 
9:4906-4913 
49. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, 
Chung JH. Cd24, a novel cancer biomarker, 
predicting disease-free survival of non-small 
cell lung carcinomas: A retrospective study of 
prognostic factor analysis from the viewpoint 
of forthcoming (seventh) new tnm classification. 
J Thorac Oncol. 5:649-657 
50. Aigner S, Ramos CL, Hafezi-Moghadam A, 
Lawrence MB, Friederichs J, Altevogt P, Ley K. 
Cd24 mediates rolling of breast carcinoma cells 
on p-selectin. Faseb J. 1998, 12:1241-1251 
51. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, 
Ji XD, Guan DX, Gao H, Xu LY, Li EM, 
Soukiasian H, Koeffler HP, Wang XF, Xie D. 
Tumor initiating cells in esophageal squamous 
cell carcinomas express high levels of cd44. 
PLoS One. 6:e21419 
52. Moghbeli M, Abbaszadegan MR, Farshchian M, 
Montazer M, Raeisossadati R, Abdollahi A, 
Forghanifard MM. Association of PYGO2 and 
EGFR in esophageal squamous cell carcinoma. 
Med Oncol. 2013, 30:516 
53. Miele L. Notch signaling. Clin Cancer Res. 
2006, 12:1074-1079 
54. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang 
Y, Sarkar FH. Down-regulation of notch-1 
inhibits invasion by inactivation of nuclear 
factor-kappab, vascular endothelial growth 
factor, and matrix metalloproteinase-9 in 
pancreatic cancer cells. Cancer Res. 2006, 
66:2778-2784 
55. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, 
Zhou P, Yin DD, Zheng QJ, Liang L, Zhang SZ, 
Feng L, Yao LB, Yang AG, Han H, Chen JY. 
Notch activation promotes cell proliferation 
and the formation of neural stem cell-like 
colonies in human glioma cells. Mol Cell 
Biochem. 2008, 307:101-108 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 11 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
56. Miele L, Miao H, Nickoloff BJ. Notch 
signaling as a novel cancer therapeutic target. 
Curr Cancer Drug Targets. 2006, 6:313-323 
57. Mendelson J, Song S, Li Y, Maru DM, Mishra 
B, Davila M, Hofstetter WL, Mishra L. 
Dysfunctional transforming growth 
factor-beta signaling with constitutively 
active notch signaling in barrett's esophageal 
adenocarcinoma. Cancer. 117:3691-3702 
58. Klymkowsky MW, Savagner P. 
Epithelial-mesenchymal transition: A cancer 
researcher's conceptual friend and foe. Am J 
Pathol. 2009, 174:1588-1593 
59. McElhinny AS, Li JL, Wu L. Mastermind-like 
transcriptional co-activators: Emerging roles 
in regulating cross talk among multiple 
signaling pathways. Oncogene. 2008, 
27:5138-5147 
60.   Sasaki K, Natsugoe S, Ishigami S, Matsumoto 
M, Okumura H, Setoyama T, Uchikado Y, 
Kita Y, Tamotsu K, Sakamoto A, Owaki T, 
Aikou T. Significance of twist expression and 
its association with e-cadherin in esophageal 
squamous cell carcinoma. J Exp Clin Cancer 
Res. 2009, 28:158 
61. Martin TA, Goyal A, Watkins G, Jiang WG. 
Expression of the transcription factors snail, 
slug, and twist and their clinical significance 
in human breast cancer. Ann Surg Oncol. 2005, 
12:488-496 
62. Forghanifard MM, Moaven O, Farshchian M, 
Montazer M, Raeisossadati R, Abdollahi A, 
Moghbeli M, Nejadsattari T, Parivar K, 
Abbaszadegan MR. Expression analysis 
elucidates the roles of maml1 and twist1 in 
esophageal squamous cell carcinoma 
aggressiveness and metastasis. Ann Surg 
Oncol.  
63. Gaetani P, Hulleman E, Levi D, Quarto M, 
Scorsetti M, Helins K, Simonelli M, Colombo P, 
Baena y Rodriguez R. Expression of the 
transcription factor hey1 in glioblastoma: A 
preliminary clinical study. Tumori. 96:97-102 
64. Beachy PA, Karhadkar SS, Berman DM. 
Tissue repair and stem cell renewal in 
carcinogenesis. Nature. 2004, 432:324-331 
65. Ingham PW, McMahon AP. Hedgehog signaling 
in animal development: Paradigms and 
principles. Genes Dev. 2001, 15:3059-3087 
66. Aza-Blanc P, Ramirez-Weber FA, Laget MP, 
Schwartz C, Kornberg TB. Proteolysis that is 
inhibited by hedgehog targets cubitus 
interruptus protein to the nucleus and 
converts it to a repressor. Cell. 1997, 
89:1043-1053 
67. Hooper JE, Scott MP. Communicating with 
hedgehogs. Nat Rev Mol Cell Biol. 2005, 
6:306-317 
68. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott 
MP, Quinn AG. Foxm1 is a downstream target 
of gli1 in basal cell carcinomas. Cancer Res. 
2002, 62:4773-4780 
69. Johnson RL, Rothman AL, Xie J, Goodrich LV, 
Bare JW, Bonifas JM, Quinn AG, Myers RM, 
Cox DR, Epstein EH, Jr., Scott MP. Human 
homolog of patched, a candidate gene for the 
basal cell nevus syndrome. Science. 1996, 
272:1668-1671 
70. Coia LR, Minsky BD, Berkey BA, John MJ, 
Haller D, Landry J, Pisansky TM, Willett CG, 
Hoffman JP, Owen JB, Hanks GE. Outcome of 
patients receiving radiation for cancer of the 
esophagus: Results of the 1992-1994 patterns 
of care study. J Clin Oncol. 2000, 18:455-462 
71. Iyer R, Wilkinson N, Demmy T, Javle M. 
Controversies in the multimodality 
management of locally advanced esophageal 
cancer: Evidence-based review of surgery 
alone and combined-modality therapy. Ann 
Surg Oncol. 2004, 11:665-673 
72. Yoshikawa R, Nakano Y, Tao L, Koishi K, 
Matsumoto T, Sasako M, Tsujimura T, 
Hashimoto-Tamaoki T, Fujiwara Y. Hedgehog 
signal activation in oesophageal cancer 
patients undergoing neoadjuvant 
chemoradiotherapy. Br J Cancer. 2008, 
98:1670-1674 
73. Mori Y, Okumura T, Tsunoda S, Sakai Y, 
Shimada Y. Gli-1 expression is associated with 
lymph node metastasis and tumor progression 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 12 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
in esophageal squamous cell carcinoma. 
Oncology. 2006, 70:378-389 
74. Harvey K, Tapon N. The salvador-warts-hippo 
pathway - an emerging tumour-suppressor 
network. Nat Rev Cancer. 2007, 7:182-191 
75. Camargo FD, Gokhale S, Johnnidis JB, Fu D, 
Bell GW, Jaenisch R, Brummelkamp TR. Yap1 
increases organ size and expands 
undifferentiated progenitor cells. Curr Biol. 
2007, 17:2054-2060 
76. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu 
J, Chinnaiyan A, Israel MA, Goldstein LS, 
Abujarour R, Ding S, Guan KL. The role of yap 
transcription coactivator in regulating stem 
cell self-renewal and differentiation. Genes 
Dev. 24:1106-1118 
77. Zhao B, Tumaneng K, Guan KL. The hippo 
pathway in organ size control, tissue 
regeneration and stem cell self-renewal. Nat 
Cell Biol. 13:877-883 
78. Heallen T, Zhang M, Wang J, Bonilla-Claudio 
M, Klysik E, Johnson RL, Martin JF. Hippo 
pathway inhibits wnt signaling to restrain 
cardiomyocyte proliferation and heart size. 
Science. 332:458-461 
79. Ferrigno O, Lallemand F, Verrecchia F, L'Hoste 
S, Camonis J, Atfi A, Mauviel A. Yes-associated 
protein (yap65) interacts with smad7 and 
potentiates its inhibitory activity against 
tgf-beta/smad signaling. Oncogene. 2002, 
21:4879-4884 
80. Komuro A, Nagai M, Navin NE, Sudol M. Ww 
domain-containing protein yap associates with 
erbb-4 and acts as a co-transcriptional 
activator for the carboxyl-terminal fragment of 
erbb-4 that translocates to the nucleus. J Biol 
Chem. 2003, 278:33334-33341 
81. Strano S, Monti O, Pediconi N, Baccarini A, 
Fontemaggi G, Lapi E, Mantovani F, Damalas 
A, Citro G, Sacchi A, Del Sal G, Levrero M, 
Blandino G. The transcriptional coactivator 
yes-associated protein drives p73 gene-target 
specificity in response to DNA damage. Mol 
Cell. 2005, 18:447-459 
82. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van 
Wijnen AJ, Stein JL, Lian JB, Stein GS. 
Tyrosine phosphorylation controls 
runx2-mediated subnuclear targeting of yap to 
repress transcription. Embo J. 2004, 
23:790-799 
83. Steinhardt AA, Gayyed MF, Klein AP, Dong J, 
Maitra A, Pan D, Montgomery EA, Anders RA. 
Expression of yes-associated protein in 
common solid tumors. Hum Pathol. 2008, 
39:1582-1589 
84. Overholtzer M, Zhang J, Smolen GA, Muir B, 
Li W, Sgroi DC, Deng CX, Brugge JS, Haber 
DA. Transforming properties of yap, a 
candidate oncogene on the chromosome 11q22 
amplicon. Proc Natl Acad Sci U S A. 2006, 
103:12405-12410 
85. Muramatsu T, Imoto I, Matsui T, Kozaki K, 
Haruki S, Sudol M, Shimada Y, Tsuda H, 
Kawano T, Inazawa J. Yap is a candidate 
oncogene for esophageal squamous cell 
carcinoma. Carcinogenesis. 32:389-398 
86. Cronwright G, Le Blanc K, Gotherstrom C, 
Darcy P, Ehnman M, Brodin B. Cancer/testis 
antigen expression in human mesenchymal 
stem cells: Down-regulation of ssx impairs cell 
migration and matrix metalloproteinase 2 
expression. Cancer Res. 2005, 65:2207-2215 
87. Coral S, Sigalotti L, Altomonte M, Engelsberg 
A, Colizzi F, Cattarossi I, Maraskovsky E, 
Jager E, Seliger B, Maio M. 
5-aza-2'-deoxycytidine-induced expression of 
functional cancer testis antigens in human 
renal cell carcinoma: Immunotherapeutic 
implications. Clin Cancer Res. 2002, 
8:2690-2695 
88. Haffner AC, Tassis A, Zepter K, Storz M, 
Tureci O, Burg G, Nestle FO. Expression of 
cancer/testis antigens in cutaneous t cell 
lymphomas. Int J Cancer. 2002, 97:668-670 
89. Zendman AJ, de Wit NJ, van Kraats AA, 
Weidle UH, Ruiter DJ, van Muijen GN. 
Expression profile of genes coding for 
melanoma differentiation antigens and 
cancer/testis antigens in metastatic lesions of 
human cutaneous melanoma. Melanoma Res. 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 13 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
2001, 11:451-459 
90. Soulez M, Saurin AJ, Freemont PS, Knight JC. 
Ssx and the synovial-sarcoma-specific 
chimaeric protein syt-ssx co-localize with the 
human polycomb group complex. Oncogene. 
1999, 18:2739-2746 
91. Sakurai T, Itoh K, Higashitsuji H, Nagao T, 
Nonoguchi K, Chiba T, Fujita J. A cleaved form 
of mage-a4 binds to miz-1 and induces 
apoptosis in human cells. J Biol Chem. 2004, 
279:15505-15514 
92. Peikert T, Specks U, Farver C, Erzurum SC, 
Comhair SA. Melanoma antigen a4 is 
expressed in non-small cell lung cancers and 
promotes apoptosis. Cancer Res. 2006, 
66:4693-4700 
93. Bergeron A, Picard V, LaRue H, Harel F, 
Hovington H, Lacombe L, Fradet Y. High 
frequency of mage-a4 and mage-a9 expression 
in high-risk bladder cancer. Int J Cancer. 2009, 
125:1365-1371 
94. Forghanifard MM, Gholamin M, Farshchian M, 
Moaven O, Memar B, Forghani MN, Dadkhah 
E, Naseh H, Moghbeli M, Raeisossadati R, 
Abbaszadegan MR. Cancer-testis gene 
expression profiling in esophageal squamous 
cell carcinoma: Identification of specific tumor 
marker and potential targets for 
immunotherapy. Cancer Biol Ther. 12:191-197 
95. Tada T, Tada M. Toti-/pluripotential stem cells 
and epigenetic modifications. Cell Struct Funct. 
2001, 26:149-160 
96. Fraga MF, Esteller M. DNA methylation: A 
profile of methods and applications. 
Biotechniques. 2002, 33:632, 634, 636-649 
97. Lee TI, Jenner RG, Boyer LA, Guenther MG, 
Levine SS, Kumar RM, Chevalier B, Johnstone 
SE, Cole MF, Isono K, Koseki H, Fuchikami T, 
Abe K, Murray HL, Zucker JP, Yuan B, Bell 
GW, Herbolsheimer E, Hannett NM, Sun K, 
Odom DT, Otte AP, Volkert TL, Bartel DP, 
Melton DA, Gifford DK, Jaenisch R, Young RA. 
Control of developmental regulators by 
polycomb in human embryonic stem cells. Cell. 
2006, 125:301-313 
98. Tsuji-Takayama K, Inoue T, Ijiri Y, Otani T, 
Motoda R, Nakamura S, Orita K. 
Demethylating agent, 5-azacytidine, reverses 
differentiation of embryonic stem cells. 
Biochem Biophys Res Commun. 2004, 
323:86-90 
99. Jenuwein T, Allis CD. Translating the histone 
code. Science. 2001, 293:1074-1080 
100. Sparmann A, van Lohuizen M. Polycomb 
silencers control cell fate, development and 
cancer. Nat Rev Cancer. 2006, 6:846-856 
101. Chen H, Tu SW, Hsieh JT. Down-regulation of 
human dab2ip gene expression mediated by 
polycomb ezh2 complex and histone 
deacetylase in prostate cancer. J Biol Chem. 
2005, 280:22437-22444 
102. Fujii S, Ochiai A. Enhancer of zeste homolog 2 
downregulates e-cadherin by mediating 
histone h3 methylation in gastric cancer cells. 
Cancer Sci. 2008, 99:738-746 
103. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste 
homologue 2 (ezh2) down-regulates runx3 by 
increasing histone h3 methylation. J Biol 
Chem. 2008, 283:17324-17332 
104. Varambally S, Dhanasekaran SM, Zhou M, 
Barrette TR, Kumar-Sinha C, Sanda MG, 
Ghosh D, Pienta KJ, Sewalt RG, Otte AP, 
Rubin MA, Chinnaiyan AM. The polycomb 
group protein ezh2 is involved in progression of 
prostate cancer. Nature. 2002, 419:624-629 
105. Yamada A, Fujii S, Daiko H, Nishimura M, 
Chiba T, Ochiai A. Aberrant expression of ezh2 
is associated with a poor outcome and p53 
alteration in squamous cell carcinoma of the 
esophagus. Int J Oncol. 38:345-353 
106. He XT, Cao XF, Ji L, Zhu B, Lv J, Wang DD, Lu 
PH, Cui HG. Association between bmi1 and 
clinicopathological status of esophageal 
squamous cell carcinoma. World J 
Gastroenterol. 2009,     15:2389-2394 
107. Alvarez-Garcia I, Miska EA. Microrna functions 
in animal development and human disease. 
Development. 2005, 132:4653-4662 
108. Garzon R, Calin GA, Croce CM. Micrornas in 
cancer. Annu Rev Med. 2009, 60:167-179 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 14 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
109. Ambros V. Microrna pathways in flies and 
worms: Growth, death, fat, stress, and timing. 
Cell. 2003, 113:673-676 
110. Cullen BR. Transcription and processing of 
human microrna precursors. Mol Cell. 2004, 
16:861-865 
111. Kim VN, Han J, Siomi MC. Biogenesis of small 
rnas in animals. Nat Rev Mol Cell Biol. 2009, 
10:126-139 
112. Filipowicz W, Bhattacharyya SN, Sonenberg N. 
Mechanisms of post-transcriptional regulation 
by micrornas: Are the answers in sight? Nat 
Rev Genet. 2008, 9:102-114 
113. He L, Thomson JM, Hemann MT, 
Hernando-Monge E, Mu D, Goodson S, Powers 
S, Cordon-Cardo C, Lowe SW, Hannon GJ, 
Hammond SM. A microrna polycistron as a 
potential human oncogene. Nature. 2005, 
435:828-833 
114. Calin GA, Croce CM. Microrna signatures in 
human cancers. Nat Rev Cancer. 2006, 
6:857-866 
115. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, 
Mendell JT. C-myc-regulated micrornas 
modulate e2f1 expression. Nature. 2005, 
435:839-843 
116. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. 
Microrna-21 targets tumor suppressor genes in 
invasion and metastasis. Cell Res. 2008, 
18:350-359 
117. Bloomston M, Frankel WL, Petrocca F, Volinia 
S, Alder H, Hagan JP, Liu CG, Bhatt D, 
Taccioli C, Croce CM. Microrna expression 
patterns to differentiate pancreatic 
adenocarcinoma from normal pancreas and 
chronic pancreatitis. Jama. 2007, 
297:1901-1908 
118. Feber A, Xi L, Luketich JD, Pennathur A, 
Landreneau RJ, Wu M, Swanson SJ, Godfrey 
TE, Litle VR. Microrna expression profiles of 
esophageal cancer. J Thorac Cardiovasc Surg. 
2008, 135:255-260; discussion 260 
119. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, 
Bowman ED, Yanaihara N, Yuen ST, Chan TL, 
Kwong DL, Au GK, Liu CG, Calin GA, Croce 
CM, Harris CC. Microrna expression profiles 
associated with prognosis and therapeutic 
outcome in colon adenocarcinoma. Jama. 2008, 
299:425-436 
120. Godlewski J, Nowicki MO, Bronisz A, Williams 
S, Otsuki A, Nuovo G, Raychaudhury A, 
Newton HB, Chiocca EA, Lawler S. Targeting 
of the bmi-1 oncogene/stem cell renewal factor 
by microrna-128 inhibits glioma proliferation 
and self-renewal. Cancer Res. 2008, 
68:9125-9130 
121. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, 
Johnson E, Marcinkiewicz L, Jiang J, Yang Y, 
Schmittgen TD, Lopes B, Schiff D, Purow B, 
Abounader R. Microrna-34a inhibits 
glioblastoma growth by targeting multiple 
oncogenes. Cancer Res. 2009, 69:7569-7576 
122. Gregory PA, Bert AG, Paterson EL, Barry SC, 
Tsykin A, Farshid G, Vadas MA, Khew-Goodall 
Y, Goodall GJ. The mir-200 family and mir-205 
regulate epithelial to mesenchymal transition 
by targeting zeb1 and sip1. Nat Cell Biol. 2008, 
10:593-601 
123. Park SM, Gaur AB, Lengyel E, Peter ME. The 
mir-200 family determines the epithelial 
phenotype of cancer cells by targeting the 
e-cadherin repressors zeb1 and zeb2. Genes 
Dev. 2008, 22:894-907 
124. Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, 
Huang Q, Fang GQ, Li EM. Mirna profile in 
esophageal squamous cell carcinoma: 
Downregulation of mir-143 and mir-145. World 
J Gastroenterol. 17:79-88 
125. Zhang M, Zhou S, Zhang L, Zhang J, Cai H, 
Zhu J, Huang C, Wang J. Mir-518b is 
down-regulated, and involved in cell 
proliferation and invasion by targeting rap1b 
in esophageal squamous cell carcinoma. FEBS 
Lett. 586:3508-3521 
126. Cai EH, Gao YX, Wei ZZ, Chen WY, Yu P, Li K. 
Serum mir-21 expression in human esophageal 
squamous cell carcinomas. Asian Pac J Cancer 
Prev. 13:1563-1567 
127. Kurashige J, Kamohara H, Watanabe M, 
Tanaka Y, Kinoshita K, Saito S, Hiyoshi Y, 
   
Ivy Union Publishing | http: //www.ivyunion.org March 10, 2013 | Volume 1 | Issue 1  
Page 15 of 15 Meysam Moghbeli et al. American Journals of Cancer Science 2013, 1:8-22 
Iwatsuki M, Baba Y, Baba H. Serum 
microrna-21 is a novel biomarker in patients 
with esophageal squamous cell carcinoma. J 
Surg Oncol. 106:188-192 
128. Xin M, Small EM, Sutherland LB, Qi X, 
McAnally J, Plato CF, Richardson JA, 
Bassel-Duby R, Olson EN. Micrornas mir-143 
and mir-145 modulate cytoskeletal dynamics 
and responsiveness of smooth muscle cells to 
injury. Genes Dev. 2009, 23:2166-2178 
129. Xu N, Papagiannakopoulos T, Pan G, Thomson 
JA, Kosik KS. Microrna-145 regulates oct4, 
sox2, and klf4 and represses pluripotency in 
human embryonic stem cells. Cell. 2009, 
137:647-658 
130. Gilad S, Meiri E, Yogev Y, Benjamin S, 
Lebanony D, Yerushalmi N, Benjamin H, 
Kushnir M, Cholakh H, Melamed N, Bentwich 
Z, Hod M, Goren Y, Chajut A. Serum micrornas 
are promising novel biomarkers. PLoS One. 
2008, 3:e3148 
131. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, 
Yu J, Poon TC, Ng SS, Sung JJ. Differential 
expression of micrornas in plasma of patients 
with colorectal cancer: A potential marker for 
colorectal cancer screening. Gut. 2009, 
58:1375-1381 
132. Resnick KE, Alder H, Hagan JP, Richardson DL, 
Croce CM, Cohn DE. The detection of 
differentially expressed micrornas from the 
serum of ovarian cancer patients using a novel 
real-time pcr platform. Gynecol Oncol. 2009, 
112:55-59 
133. Mathe EA, Nguyen GH, Bowman ED, Zhao Y, 
Budhu A, Schetter AJ, Braun R, Reimers M, 
Kumamoto K, Hughes D, Altorki NK, Casson 
AG, Liu CG, Wang XW, Yanaihara N, 
Hagiwara N, Dannenberg AJ,  Miyashita M, 
Croce CM, Harris CC. Microrna expression in 
squamous cell carcinoma and adenocarcinoma 
of the esophagus: Associations with survival. 
Clin Cancer Res. 2009, 15:6192-6200 
134. Luthra R, Singh RR, Luthra MG, Li YX, 
Hannah C, Romans AM, Barkoh BA, Chen SS, 
Ensor J, Maru DM, Broaddus RR, Rashid A, 
Albarracin CT. Microrna-196a targets annexin 
a1: A microrna-mediated mechanism of 
annexin a1 downregulation in cancers. 
Oncogene. 2008, 27:6667-6678 
135. Croce CM. Causes and consequences of 
microrna dysregulation in cancer. Nat Rev 
Genet. 2009, 10:704-714 
136. Moserle L, Ghisi M, Amadori A, Indraccolo S. 
Side population and cancer stem cells: 
Therapeutic implications. Cancer Lett. 288:1-9 
137. Korpal M, Lee ES, Hu G, Kang Y. The mir-200 
family inhibits epithelial-mesenchymal 
transition and cancer cell migration by direct 
targeting of e-cadherin transcriptional 
repressors zeb1 and zeb2. J Biol Chem. 2008, 
283:14910-14914 
138. Nakamura T, Tsuchiya K, Watanabe M. 
Crosstalk between wnt and notch signaling in 
intestinal epithelial cell fate decision. J 
Gastroenterol. 2007, 42:705-710 
139. Yanai K, Nakamura M, Akiyoshi T, Nagai S, 
Wada J, Koga K, Noshiro H, Nagai E, 
Tsuneyoshi M, Tanaka M, Katano M. Crosstalk 
of hedgehog and wnt pathways in gastric 
cancer. Cancer Lett. 2008, 263:145-156 
140. Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, 
Moller M, Nyakas M, Hansen GL, Gaudernack 
G, Aamdal S. Telomerase peptide vaccination 
in nsclc: A phase ii trial in stage iii patients 
vaccinated after chemoradiotherapy and an 
8-year update on a phase i/ii trial. Clin Cancer 
Res. 17:6847-6857 
141. Jayasekera BA, Bacon AD, Whitfield PC. 
Management of glioblastoma multiforme in 
pregnancy. J Neurosurg. 116:1187-1194 
 
 
 
